Article / Case Report

"The Individualized Antiplatelet Therapy in a Patient with Renal Insufficiency Following Percutaneous Coronary Intervention: A Case Report"

Jing-Xiu Li, Yang Li, Xin-Li, Ye-Ping Chen, De-Jun Xia, En-Ze Jin, Xue-Qi Li* 

Department of Cardiology, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China 

*Corresponding author: Xue-Qi Li, Department of Cardiology, the Fourth Affiliated Hospital of Harbin Medical University. No.37 Yiyuan Street, Nangang District, Harbin City, Heilongjiang Province, China 150001, China.

Tel: +8645182576775/ 85939052; Fax: +864518256796; Emil: 

Received Date: 24 May, 2018; Accepted Date: 13 August, 2018; Published Date: 17 August, 2018

1.            Introduction 

Clopidogrel plays a key role in inhibiting platelet adhesion, activation, and aggression. It has been widely recommended by current guidelines in patients undergoing PCI. We discuss the clinical application of VerifyNow P2Y12 assay in the evaluation of clopidogrel resistant in this patient with clopdiogrel resistance. We also introduced the hepatic cytochromes (CYP450) enzymes metabolic pathways of clopidogrel and the pivotal role of CYP2C19 genotype on outcome of clopidogrel therapy. However, under the circumstance of discontinuing clopidogrel, this clopidogrel resistance patient with renal insufficient suffered from a cerebral hemorrhage. The optimal individualized antiplatelet therapy in patients with clopidogrel resistance following PCI, especially concurrence renal insufficient still need further to be studied. 

2.            Keywords: CYP2C19 Genotype; Renal Insufficiency; Verifynow Antiplatelet Assay

3.            Case Presentation 

3.1.              Clinical Data 

A 62-year-old coronary heart disease man who had experienced paroxysmal ischemic chest pain for fifteen years came to the cardiology department after an episode of chest pain at ten o’clock on September 12, 2016. 

3.2.              Past History 

He had three stents implanted in 2001, three stents implanted in 2008, and one stent implanted in 2014. He was with no history of hypertension and diabetes mellitus. He was without hepatitis and tuberculosis. 

3.3.              Personal History

No history of smoking or drinking. 

3.4.              Course of Analysis 

His blood pressure at presentation was 100/70 mmHg, heart rate 70 bpm, afebrile, oxygen saturation (SaO2 99%). His bed side Electrocardiogram (ECG) showed atrial fibrillation. Biochemistry test results revealed renal insufficiency (creatinine 180.9 umol/L), and high total cholesterol 5.22 mmol/L. Creatine Kinase-MB (CK-MB) 11 U/L and B-natriuretic peptide (BNP) 2516 pg/mml were also present.

On hospital day2, the patient underwent coronary angiography on September 13, 2016. The imaging showed that the patency after left main coronary artery stenting, the patency of the stent of the proximal Left Anterior Descending (LAD), while 90% stenosis of the distal LAD. There is about 90% obstruction of the first diagonal branch of the LAD. The stent patency was in the proximal left circumflex coronary artery. There was the complete occlusion in the distal of the left circumflex coronary artery. Restenosis after stent implantation was in the right coronary artery with non-calcified and mixed plaques, and the complete occlusion of the middle of right coronary artery. We implanted a Giwei stent2.5*28 mmon the distal Left Anterior Descending (LAD). Angiography revealed a good result at the site of stent deployment. 

We tested the platelet aggregation with the PFA-100 platelet function analyzer in hospital outpatient department (2016-10-16). The results showed that ACA 8.6% (55.0-90.0%) and ADP 53.1% (55.0-90.0%). The blood routine examination showed PLT240 ×109/L. According to the severity of coronary artery disease, the incidence of chest distress recently, and the platelet function monitoring by PFA-100 platelet function analyzer, we adjust his antiplatelet therapy using aspirin 100 mg QD + ticagrelor 90 mg BID and other routine treatment (2016-10-16).

Forty days after his discharge (2016-10-24), the patient returned with chest congestion and dyspnea. His blood pressure at presentation was 110/70 mmHg, heart rate 78 bpm, afebrile, oxygen saturation (SaO2 99%). We performed a complete echocardiographic examination identifying the patient with left ventricular Ejection Fraction (EF) about 39% and diffuse hypokinetic left ventricular wall motion and the result was similar with previous one. He discharged from our hospital in 2016-10-27. We thought that dyspnea might be due to the side effect of ticagrelor, so we adjust the antiplatelet agents once again, using aspirin 100 mg QD and clopidogrel 75 mg QD. We tested the platelet function with the VerifyNow antiplatelet assay (2016-11-09). Results showed that P2Y12 Reaction Unit (PRU) value of 330 (reference range for PRU from 95 to 208 PRU), with the rate of inhibition of 0%, and baseline 329 PRU. The result of VerifyNow platelet-function testing showed the patient with high on-clopidogrel platelet reactivity, which means the patient with clopidogrel resistance. We detected CYP2C19 genotyping for clopidogrel in 2016-11-11, with the result of genetic testing CYP2C19*3/*3 (636AA, 681 GG). We readjusted his antiplatelet therapy using aspirin 100 mg QD + Clopidogrel 75mg QD+ Cilostazol 100 mg BID after discharge from the hospital. We did telephone follow-up after discharge and got feedback that the patient occurred chest distress and fatigue once in a while, without severe chest pains and dyspnea. The patient came to subsequent visit in 2016-11-21. After the routine assessment, we did the platelet function with the VerifyNow antiplatelet assay (2016-11-09). Results showed that P2Y12 Reaction Unit (PRU) value of 276PRU, with the rate of inhibition of 8%, and baseline 299 PRU. The ECG revealed atrial fibrillation and ST-T change. The patient was instructed in the use of aspirin 100 mg QD + Clopidogrel 75mg QD+ Cilostazol 100 mg BID. We informed him to contact us if he felt discomfort immediately. However, he didn’t follow the doctor’s advice due to personal reason, stopping Cilostazol and taking clopidogrel irregularly. 

He was admitted to our department with an outbreak of dizziness and vomiting for 1 hour in 2017-01-14. The patient said that he felt dizzy and then vomited gastric content after defaecation. Physical examination at admission revealed an irregular heart rate of 75 beats/min (bmp), blood pressure 168/80 mmHg, respiratory rate 20 per min. Bilateral muscle strength is asymmetry and the right side of the limb was graded as grade 4. Bilateral pathological signs were negative. The ECG revealed atrial fibrillation and ST-T change. Cranial CT2017-01-14: left thalamic hemorrhage breaking into ventricular, left frontal lobe encephalomalacia and brain atrophy. Lung CT: bilateral interstitial pneumonia, upper lobe bronchiectasis, and bilateral pleural effusion. A hemogram showed a high D-dimer 8.26 mg/L and fibrinogen 6.32g/L. Biochemistry test results revealed renal insufficiency (creatinine 439.9 umol/L), and total cholesterol 2.42 mmol/L. Creatine Kinase-MB (CK-MB) 14 U/L were also present. After acute consultant, the patient was transferred to the department of neurology for further treatment. He was discharged from neurology department after the specialized treatment. 

Diagnosis: The final diagnosis was coronary atherosclerotic heart disease and unstable angina after percutaneous coronary stents placement, with class III systolic heart failure, atrial fibrillation, cerebral hemorrhage, and chronic renal failure. 

4.            Discussion 

The patient has been treated in our department for several times since 2014. He had eight stents implanted totally, without a history of hypertension and diabetes mellitus. We did platelet function analysis by LTA and Verifynow after his last percutaneous coronary intervention with stenting. The results showed clopidogrel resistance in this patient. Furthermore, we explicit the CYP2C19 loss of function allele *3 variants might be responsible for clopidogrel resistance. We weight the risk of bleeding and ischemic event by the platelet function analysis and CHA2DS2-VASC/HAS-BLED score. Based on these results, we did adjust the antiplatelet therapy with aspirin + ticagrelor or aspirin + clopidogrel + cilostazol. However, the patient was intolerable to the changes. Due to personal reasons, he did not follow the doctor’s advice, stopping Cilostazole and taking clopidogrel irregularly. Finally, this renal insufficient patient with clopidogrel resistance suffered a cerebral hemorrhage.

Chronic Kidney Disease (CKD) is related to an increased risk of cardiovascular adverse events in patients following percutaneous coronary intervention, even if in patients with the renal function only moderately disturbed [1,2]. Previous studies have found that patients with chronic kidney disease might have the less therapeutic benefit of antiplatelet therapy [3,4]. The relationship between the renal function and the platelet reactivity is the current research hotspot. Clinical data on the relationship between the renal function and the platelet reactivity in patients on dual antiplatelet therapy (aspirin and clopidogrel) are controversial [5-9]. 

Several international guidelines have already recommended dual use of aspirin and clopidogrel for the prevention of ACS and MACE after Percutaneous Coronary Intervention (PCI) [10-13]. It is well known that clopidogrel has a wide variability in platelet responsive. Thought antiplatelet treatment of clopidogrel correctly, there still exists 5-10% of patient’s experience thrombosis events after percutaneous coronary intervention [14,15]. In general, clopidogrel resistance refers to the occurrence of adverse cardiovascular events despites adequate antiplatelet treatment and compliance [16,17]. Clopidogrel resistance also call non-responsiveness. It has been published several definitions for clopidogrel resistance based on Light Transmission Aggregometry (LTA) assay: <10% absolute decrease in LTA-ADP max from the baseline, or LTA-ADP max value >50% during treatment [18,19]. Recently, the Verifynow-P2Y12 assay is considered to be a reliable, accurate, sensitive device for clinical monitoring platelet inhibition with clopidogrel [20,21]. 

Clopidogrel, a thienopyridine, is a prodrug. In liver, about 15% absorbed clopidogrel is metabolized to an active metabolite by hepatic cytochromes (CYP450) enzymes in a 2-step process. It has been proven that CYP2C19, CYP1A2, CYP2B6 isoenzymes have a critical role in the first step, and CYP2C19, CYP3A4, CYP2C9 play a crucial role for the second step. By irreversibly binding of the P2Y12 ADP receptor on platelet surface, Clopidogrel inhibits the platelet activation and aggregation [22]. Various factors have been implicated in clopidogrel resistance, for example, clinical, cellular, and genetic factors etc. [23,24]. First, Because of patient noncompliance, clopidogrel treatment can’t continue. Second, Studies have demonstrated that clopidogrel resistance is related to gene polymorphism [25,26]. Concerning clopidogrel metabolism in health individuals, carriers of a reduced-function allele of CYP2C19 had 30% lower levels of the active clopidogrel metabolite and a 25% relative reduction in platelet inhibition ex vivo [27]. It maybe point out that CYP2C19 does affect the pharmacodynamics of clopidogrel in patients as well. In clinical research, patients with acute MI on clinical who sustained subsequent cardiovascular events were more likely to carry CYP2C19 loss-of-function alleles compared to control group, showing an increased effect particularly in patients who underwent PCI [28]. In another study including patients treated with clopidogrel, carriers of a reduced-function CYP2C19 allele had significantly lower levels of the active metabolite of clopidogrel with diminished platelet inhibition and a higher rate of MACE (major adverse cardiovascular events) [29]. The percentage of poor CYP2C19 metabolizer subjects is about 2-4.8% worldwide, with a particularly high incidence of 22.5% among East Asians [30,31]. Furthermore, the interaction between drug-drug many is associated with the variability in the absorption of clopidogrel. Concerns have been raised about the adverse cardiovascular effects of Proton Pump Inhibitors (PPIs) especially omeprazole in patients receiving clopidogrel [32,33]. 

As previous recommendation, a value >208 P2Y12 Receptor Units (PRU) was defined as clopidogrel resistance or high on-treatment platelet reactivity [34]. It has been accepted recently that a PRU value > 208 can well predict death, myocardial infarction or stent thrombosis [35]. It has been indicated that CYP2C19 polymorphism plays a pivotal role in clopidogrel pharmacodynamics and pharmacokinetics. Patients can be divided into four categories based on this clopidogrel metabolism genotype [36,37]. The first kind is normal metabolizer, which is also called extensive metabolizers (EMs: wild-type for the CYP2C19 polymorphisms). The second kind is poor metabolizers (PMs: homozygous or compound heterozygous genotypes for the LOF CYP2C19 polymorphisms). The third is intermediate metabolizers (IMs: heterozygous genotype for the LOF CYP2C19 polymorphisms and wild type of the CYP2C19). The fourth is ultra-rapid metabolizer (UM: heterozygous or homozygous genotype for the CYP2C19*17 and wiled type of CYP2C19). It has been reported that the clopidogrel resistance with CYP2C19-loss-of-function allele may not be overcome through high loading doses and maintenance dose [38-41]. It has been recommended that patients with poor metabolizers should take the new type P2Y12 receptor inhibitor or triple antiplatelet treatment. It is known to all that ticagrelor could interfere with adenosine metabolism, leading to increased adenosine plasma concentration [42,43]. 

An increase in adenosine concentration is the reason for dyspnea. Though ticagrelor has been widely used nowadays, we should pay attention to its side effect, especially dyspnea. The clinical outcome of the patient reminds that East Asian patients might have the different risk profiles for both thromboembolism and hemorrhagic tendency compared with white patients [44,45]. Though East Asian patients have a higher level of on-treatment platelet reactivity, clinical data signified that the clinical ischemic events with East Asian patients are similar to white patients after PCI [46]. Perhaps, there might be a different ‘therapeutic window’ of on-treatment platelet reactivity in East Asian patients. It has been reported that increased bleeding risk in patients with impaired renal function [47]. We also speculate that the impaired renal function in this patient with clopdiogrel resistance may also contribute to the cerebral hemorrhage. In conclusion, the optimal individualized antiplatelet therapy in patients with clopidogrel resistance following PCI, especially concurrence renal insufficient still need further to be studied. 

5.            Acknowledgement 

This study was supported by the Science Fund for Distinguished Young Scholars from the Fourth Affiliated Hospital of Harbin Medical University (No: HYDSYJQ201504). The funders had no role in this study design, data collection and analysis, decision to publish, or preparation of the manuscript.

1.            Shaw JA, Andrianopoulos N, Duffy S, Walton AS, Clark D, et al (2008) Melbourne Interventional Group. Renal impairment is an independent predictor of adverse events post coronary intervention in patients with and without drug-eluting stents. Cardiovasc Revasc Med 9: 218-223.

2.            Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-305.

3.            Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, et al. (2002) Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. Acc Current Journal Review 20: 2411-2420.

4.            Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, et al (2001) Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358: 527-533.

5.            Angiolillo DJ, Bernardo E, Capodanno D, Vivas D, Sabaté M, et al. (2010) Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. J Am Coll Cardiol 55: 1139-1146.

6.            Park SH, Kim W, Park CS, Kang WY, Hwang SH, et al. (2009) Comparison of clopidogrel responsiveness in patients with versus without chronic renal failure. Am J Cardiol 104: 1292-1295.

7.            Htun P, Fateh-Moghadam S, Bischofs C, Banya W, Müller K, et al. (2011) Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention. J Am Soc Nephrol 22: 627-633.

8.            Choi HI, Ahn JM, Kang SH, Lee PH, Kang SJ, et al. (2017) Prevalence, Management, and Long-Term (6-Year) Outcomes of Atrial Fibrillation Among Patients Receiving Drug-Eluting Coronary Stents. JACC Cardiovasc Interv 10: 1075-1085.

9.            Mangiacapra F, Cavallari I, Barbato E, Ricottini E, Patti G, et al. (2014) Impact of chronic kidney disease on platelet reactivity and outcomes of patients receiving clopidogrel and undergoing percutaneous coronary intervention. American Journal of Cardiology 113: 1124-1129.

10.            Kanagaratnam L, Kowey P, Whalley D (2017) Pharmacological Therapy for Rate and Rhythm Control for Atrial Fibrillation in 2017. Heart Lung Circ 26: 926-933.

11.            CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 348: 1329-1339.

12.            Peters RJ, Mehta SR, Fox KA, Zhao F, Lewis BS, et al. (2003) Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 108: 1682-1687.

13.            Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, et al. (2005) Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 294: 1224-1232.

14.            Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM (2003) Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107: 2908-2913.

15.            Wang TH, Bhatt DL, Topol EJ (2006) Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 27: 647-654.

16.            Gurbel PA, Tantry US (2006) Drug insight: Clopidogrel nonresponsiveness. Nat Clin Pract Cardiovasc Med 3: 387-395.

17.            Gurbel PA, Tantry US (2006) Aspirin and clopidogrel resistance: consideration and management. J Interv Cardiol 19: 439-448.

18.            Müller I, Besta F, Schulz C, Massberg S, Schönig A, et al. (2003) Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 89: 783-787.

19.            Brar SS, ten Berg J, Marcucci R, Price MJ, Valgimigli M, et al. (2011) Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol 58: 1945-1954.

20.            Price MJ, Angiolillo DJ, Teirstein PS, Lillie E, Manoukian SV, et al. (2011) Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation 124: 1132-1137.

21.            Wang TH, Bhatt DL, Topol EJ (2006) Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 27: 647-654.

22.            Golukhova EZ, Ryabinina MN, Bulaeva NI, Grigorian MV, Kubova MCh, et al. (2015) Clopidogrel response variability: impact of genetic polymorphism and platelet biomarkers for predicting adverse outcomes poststenting. Am J Ther 22: 222-230.

23.            Tantry US, Gesheff M, Liu F, Bliden KP, Gurbel PA (2014) Resistance to antiplatelet drugs: what progress has been made? Expert Opin Pharmacother 15: 2553-2564.

24.            Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, et al. (2007) Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 49: 1505-1516.

25.            Kubica A, Kozinski M, Grzesk G, Fabiszak T, Navarese EP, et al. (2011) Genetic determinants of platelet response to clopidogrel. J Thromb Thrombolysis 32: 459-466.

26.            Sibbing D, Stegherr J, Latz W, Koch W, Mehilli J, et al. (2009) Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J 30: 916-922.

27.            Hulot JS, Bura A, Villard E, Azizi M, Remones V, et al. (2006) Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108: 2244-2247.

28.            Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, et al. (2009) French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360: 363-375.

29.            Tang XF, Wang J, Zhang JH, Meng XM, Xu B, et al. (2013) Effect of the CYP2C19 2 and 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention. Eur J Clin Pharmacol 69: 1103-1112.

30.            Grosdidier C, Quilici J, Loosveld M, Camoin L, Moro PJ, et al. (2013) Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications. Am J Cardiol 111: 985-990.

31.            Jeong YH (2014) "East asian paradox": challenge for the current antiplatelet strategy of "one-guideline-fits-all races" in acute coronary syndrome. Curr Cardiol Rep 16: 485.

32.            Drepper MD, Spahr L, Frossard JL (2012) Clopidogrel and proton pump inhibitors--where do we stand in 2012? World J Gastroenterol 18: 2161-2171.

33.            Goodman SG, Clare R, Pieper KS, Nicolau JC, Storey RF, et al. (2012) Platelet Inhibition and Patient Outcomes Trial Investigators. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Circulation 125: 978-986.

34.            Zhang L, Chen Y, Jin Y, Qu F, Li J, et al. (2013) Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients. Thromb Res 132: 81-87.

35.            Stone GW, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann FJ, et al. (2013) ADAPT-DES Investigators. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 382: 614-623.

36.            Liu X, Luo Y, Lai Y, Yao Y, Li J, et al. (2016) Effect of genetic and coexisting polymorphisms on platelet response to clopidogrel in Chinese Han patients with acute coronary syndrome. J Genet 95: 231-237.

37.            Wallentin L, James S, Storey RF, Armstrong M, Barratt BJ, et al. (2010) PLATO investigators. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 376: 1320-1328.

38.            Zhang L, Yang J, Zhu X, Wang X, Peng L, et al. (2015) Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention- a systematic review and meta-analysis. Thromb Res 135: 449-458.

39.            Xie X, Ma YT, Yang YN, Li XM, Ma X, et al. (2013) CYP2C19 phenotype, stent thrombosis, myocardial infarction, and mortality in patients with coronary stent placement in a Chinese population. PLoS One 8: e59344.

40.            Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, et al. (2013) Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther 94: 317-323.

41.            Bhatt DL (2009) Tailoring antiplatelet therapy based on pharmacogenomics: how well do the data fit? JAMA 302: 896-897.

42.            Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, et al. (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361: 1045-1057.

43.            James SK, Storey RF, Khurmi NS, Husted S, Keltai M, et al. (2012) Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. Circulation 125: 2914-2921.

44.            Goto S, Huang CH, Park SJ, Emanuelsson H, Kimura T (2015) Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study. Circ J 79: 2452-2460.

45.            Park KH, Jeong MH, Ahn Y, Ahn TH, Seung KB, et al. (2016) Comparison of short-term clinical outcomes between ticagrelor versus clopidogrel in patients with acute myocardial infarction undergoing successful revascularization; from Korea Acute Myocardial Infarction Registry-National Institute of Health. Int J Cardiol 215: 193-200.

46.            Levine GN, Jeong YH, Goto S, Anderson JL, Huo Y, et al. (2014) World heart federation expert consensus statement on antiplatelet therapy in east asian patients with ACS or undergoing PCI. Glob Heart 9: 457-467.

Breet NJ, de Jong C, Bos WJ, van Werkum JW, Bouman HJ, et al. (2014) The impact of renal function on platelet reactivity and clinical outcome in patients undergoing percutaneous coronary intervention with stenting. Thromb Haemost 112: 1174-1181.

Citation: Li JX, Li Y, Xin-Li, Chen YP, Xia DJ, et al. (2018) The Individualized Antiplatelet Therapy in a Patient with Renal Insufficiency Following Percutaneous Coronary Intervention: A Case Report. J Urol Ren Dis: JURD-194. DOI: 10.29011/2575-7903.000094